섬유아세포 활성화 단백질 억제제 시장 보고서(2026년)

Fibroblast activation protein inhibitors are targeted therapies used to treat fibrosis-related disorders by blocking the fibroblast activation protein (FAP) involved in tissue scarring. These small-molecule inhibitors specifically inhibit FAP activity, reducing excessive fibrous tissue formation and improving organ function by slowing fibrosis progression.

The main types of fibroblast activation protein inhibitors include small molecule inhibitors, monoclonal antibodies, and peptide inhibitors. Small molecule inhibitors are low molecular weight compounds designed to penetrate cells and inhibit FAP enzymatic activity. They are being investigated for indications such as interstitial cystitis, Crohn's disease, irritable bowel syndrome, chronic prostatitis, and others. These inhibitors can be administered orally, intravenously, or subcutaneously, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used across healthcare settings including hospitals, homecare, specialty clinics, and others.

Tariffs have raised costs in the fibroblast activation protein inhibitors market by affecting imports of small-molecule compounds, biologics, and peptide synthesis materials. Intravenous and injectable therapies are most impacted, particularly in North America and Europe due to dependence on imported biopharmaceutical inputs. Hospital pharmacies face higher drug acquisition costs. Positively, tariffs are encouraging local drug development and fibrosis-focused biomanufacturing.

The fibroblast activation protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides fibroblast activation protein inhibitors market statistics, including fibroblast activation protein inhibitors industry global market size, regional shares, competitors with a fibroblast activation protein inhibitors market share, detailed fibroblast activation protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the fibroblast activation protein inhibitors industry. This fibroblast activation protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fibroblast activation protein inhibitors market size has grown strongly in recent years. It will grow from $3.02 billion in 2025 to $3.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to fibrotic disease prevalence, unmet medical needs, pharmaceutical r&d growth, hospital specialty care, biologics evolution.

The fibroblast activation protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to precision therapeutics demand, clinical trial expansion, chronic disease burden, targeted drug approvals, specialty pharmacy growth. Major trends in the forecast period include increased focus on anti-fibrotic therapies, expansion of targeted small molecule drugs, growth of chronic inflammatory disease research, rising precision medicine adoption, pipeline expansion in fibrosis indications.

The increasing cancer incidence is expected to propel the growth of the fibroblast activation protein (FAP) inhibitors market in the coming years. Cancer is a disease characterized by the uncontrolled multiplication of abnormal cells, which can invade surrounding tissues and spread to other parts of the body. It arises in various tissues and organs and is classified based on the originating cell or tissue type. The rising incidence of cancer is attributed to aging populations, lifestyle changes, environmental factors, and improved detection methods. Fibroblast activation protein inhibitors are used in cancer treatment to target and disrupt tumor-supporting fibroblasts, enhancing both diagnostic imaging and therapeutic delivery. For instance, in August 2024, according to Macmillan Cancer Support, a UK-based charitable organization supporting cancer patients, over 3 million people in the UK were living with cancer in 2024. This figure is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing incidence of cancer is driving the growth of the fibroblast activation protein inhibitors market.

Major companies operating in the fibroblast activation protein inhibitors market are focusing on integrating SAR chelator technology with FAP to improve targeted radiopharmaceutical delivery, enhance diagnostic imaging accuracy, and increase therapeutic efficacy. SAR chelator technology uses specialized molecules that tightly bind radioactive metals, allowing precise delivery of radiopharmaceuticals to cancer cells for imaging or therapy. For instance, in December 2024, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, launched its novel optimized FAP-targeted radiopharmaceutical. This breakthrough therapy is designed for precision oncology applications, expanding Clarity's pipeline and offering a highly targeted treatment approach for cancers with high FAP expression, potentially improving both diagnostic accuracy and therapeutic outcomes.

In March 2025, Telix Pharmaceuticals Ltd., an Australia-based radiopharmaceutical company, acquired FAP-targeting theranostic radiopharmaceutical candidates developed by Professor Frank Rosch and collaborators at Johannes Gutenberg University Mainz for an undisclosed amount. By leveraging Telix's global commercial infrastructure and theranostic expertise, this acquisition aims to accelerate the development of FAP-targeting agents. The acquired assets include preclinical and clinical-stage candidates for imaging and treating a variety of cancers. Johannes Gutenberg University Mainz is a Germany-based university specializing in nuclear chemistry.

Major companies operating in the fibroblast activation protein inhibitors market are Telix Pharmaceuticals Ltd., 3B Pharmaceuticals GmbH, Heidelberg Pharma AG, Clovis Oncology, Fusion Pharmaceuticals, POINT Biopharma (Eli Lilly subsidiary), Pentixapharm AG, iTheranostics, Blue Earth Diagnostics (Bracco Group), SOFIE Biosciences (FAP radioligands), Lantheus Holdings Inc., RadioMedix Inc., ImaginAb Inc., Theragnostics Ltd., Isotopen Technologien Munchen (ITM), Q BioMed Inc., Abcam plc, Sino Biological Inc., Creative Biolabs, Bachem Holding AG

North America was the largest region in the fibroblast activation protein inhibitors market in 2025. The regions covered in the fibroblast activation protein inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fibroblast activation protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibroblast activation protein inhibitors market consists of sales of antibody-drug conjugates, radiolabeled inhibitors, and combination therapies targeting fibroblast activation protein. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibroblast Activation Protein Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses fibroblast activation protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fibroblast activation protein inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fibroblast activation protein inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Small Molecule Inhibitors; Monoclonal Antibodies; Peptide Inhibitors
• 2) By Indication: Crohn's; Irritable Bowel; Chronic Prostatitis; Other Indications
• 3) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Small Molecule Inhibitors: Protease Inhibitors; Multi-Targeted Agents
• 2) By Monoclonal Antibodies: Humanized Antibodies; Fully Human Antibodies; Bispecific Antibodies
• 3) By Peptide Inhibitors: Synthetic Peptides; Natural Peptide Derivatives; Peptide-Based Conjugates
• Companies Mentioned: Telix Pharmaceuticals Ltd.; 3B Pharmaceuticals GmbH; Heidelberg Pharma AG; Clovis Oncology; Fusion Pharmaceuticals; POINT Biopharma (Eli Lilly subsidiary); Pentixapharm AG; iTheranostics; Blue Earth Diagnostics (Bracco Group); SOFIE Biosciences (FAP radioligands); Lantheus Holdings Inc.; RadioMedix Inc.; ImaginAb Inc.; Theragnostics Ltd.; Isotopen Technologien Munchen (ITM); Q BioMed Inc.; Abcam plc; Sino Biological Inc.; Creative Biolabs; Bachem Holding AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Fibroblast Activation Protein Inhibitors Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Fibroblast Activation Protein Inhibitors Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Fibroblast Activation Protein Inhibitors Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Fibroblast Activation Protein Inhibitors Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increased Focus On Anti-Fibrotic Therapies
  • 4.2.2 Expansion Of Targeted Small Molecule Drugs
  • 4.2.3 Growth Of Chronic Inflammatory Disease Research
  • 4.2.4 Rising Precision Medicine Adoption
  • 4.2.5 Pipeline Expansion In Fibrosis Indications

5. Fibroblast Activation Protein Inhibitors Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Settings
• 5.4 Research Institutions
• 5.5 Pharmaceutical Companies

6. Fibroblast Activation Protein Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Fibroblast Activation Protein Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Fibroblast Activation Protein Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Fibroblast Activation Protein Inhibitors Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Fibroblast Activation Protein Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Fibroblast Activation Protein Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Fibroblast Activation Protein Inhibitors Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Fibroblast Activation Protein Inhibitors Market Segmentation

• 9.1. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Inhibitors, Monoclonal Antibodies, Peptide Inhibitors
• 9.2. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Crohn's, Irritable Bowel, Chronic Prostatitis, Other Indications
• 9.3. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Subcutaneous
• 9.4. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
• 9.5. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.6. Global Fibroblast Activation Protein Inhibitors Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Protease Inhibitors, Multi-Targeted Agents
• 9.7. Global Fibroblast Activation Protein Inhibitors Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Humanized Antibodies, Fully Human Antibodies, Bispecific Antibodies
• 9.8. Global Fibroblast Activation Protein Inhibitors Market, Sub-Segmentation Of Peptide Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Synthetic Peptides, Natural Peptide Derivatives, Peptide-Based Conjugates

10. Fibroblast Activation Protein Inhibitors Market Regional And Country Analysis

• 10.1. Global Fibroblast Activation Protein Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Fibroblast Activation Protein Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Fibroblast Activation Protein Inhibitors Market

• 11.1. Asia-Pacific Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Fibroblast Activation Protein Inhibitors Market

• 12.1. China Fibroblast Activation Protein Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Fibroblast Activation Protein Inhibitors Market

• 13.1. India Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Fibroblast Activation Protein Inhibitors Market

• 14.1. Japan Fibroblast Activation Protein Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Fibroblast Activation Protein Inhibitors Market

• 15.1. Australia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Fibroblast Activation Protein Inhibitors Market

• 16.1. Indonesia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Fibroblast Activation Protein Inhibitors Market

• 17.1. South Korea Fibroblast Activation Protein Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Fibroblast Activation Protein Inhibitors Market

• 18.1. Taiwan Fibroblast Activation Protein Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Fibroblast Activation Protein Inhibitors Market

• 19.1. South East Asia Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Fibroblast Activation Protein Inhibitors Market

• 20.1. Western Europe Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Fibroblast Activation Protein Inhibitors Market

• 21.1. UK Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Fibroblast Activation Protein Inhibitors Market

• 22.1. Germany Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Fibroblast Activation Protein Inhibitors Market

• 23.1. France Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Fibroblast Activation Protein Inhibitors Market

• 24.1. Italy Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Fibroblast Activation Protein Inhibitors Market

• 25.1. Spain Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Fibroblast Activation Protein Inhibitors Market

• 26.1. Eastern Europe Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Fibroblast Activation Protein Inhibitors Market

• 27.1. Russia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Fibroblast Activation Protein Inhibitors Market

• 28.1. North America Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Fibroblast Activation Protein Inhibitors Market

• 29.1. USA Fibroblast Activation Protein Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Fibroblast Activation Protein Inhibitors Market

• 30.1. Canada Fibroblast Activation Protein Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Fibroblast Activation Protein Inhibitors Market

• 31.1. South America Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Fibroblast Activation Protein Inhibitors Market

• 32.1. Brazil Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Fibroblast Activation Protein Inhibitors Market

• 33.1. Middle East Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Fibroblast Activation Protein Inhibitors Market

• 34.1. Africa Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Fibroblast Activation Protein Inhibitors Market Regulatory and Investment Landscape

36. Fibroblast Activation Protein Inhibitors Market Competitive Landscape And Company Profiles

• 36.1. Fibroblast Activation Protein Inhibitors Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Fibroblast Activation Protein Inhibitors Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Fibroblast Activation Protein Inhibitors Market Company Profiles
  • 36.3.1. Telix Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. 3B Pharmaceuticals GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Heidelberg Pharma AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Clovis Oncology Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Fusion Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

37. Fibroblast Activation Protein Inhibitors Market Other Major And Innovative Companies

• POINT Biopharma (Eli Lilly subsidiary), Pentixapharm AG, iTheranostics, Blue Earth Diagnostics (Bracco Group), SOFIE Biosciences (FAP radioligands), Lantheus Holdings Inc., RadioMedix Inc., ImaginAb Inc., Theragnostics Ltd., Isotopen Technologien Munchen (ITM), Q BioMed Inc., Abcam plc, Sino Biological Inc., Creative Biolabs, Bachem Holding AG

38. Global Fibroblast Activation Protein Inhibitors Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Fibroblast Activation Protein Inhibitors Market

40. Fibroblast Activation Protein Inhibitors Market High Potential Countries, Segments and Strategies

• 40.1 Fibroblast Activation Protein Inhibitors Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Fibroblast Activation Protein Inhibitors Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Fibroblast Activation Protein Inhibitors Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer